HC Wainwright Issues Positive Estimate for ALGS Earnings

Aligos Therapeutics, Inc. (NASDAQ:ALGS) – Research analysts at HC Wainwright boosted their Q3 2026 EPS estimates for shares of Aligos Therapeutics in a research note issued on Monday, August 10th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings per share of ($2.81) for the quarter, up from their prior estimate of ($3.16). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Aligos Therapeutics’ current full-year earnings is ($7.14) per share. HC Wainwright also issued estimates for Aligos Therapeutics’ Q4 2026 earnings at ($2.02) EPS, FY2026 earnings at ($7.41) EPS, Q1 2027 earnings at ($1.49) EPS, Q2 2027 earnings at ($1.50) EPS, Q3 2027 earnings at ($0.98) EPS, Q4 2027 earnings at ($0.40) EPS, FY2027 earnings at ($4.02) EPS, FY2028 earnings at ($2.85) EPS, FY2029 earnings at ($2.36) EPS and FY2030 earnings at ($0.71) EPS.

Several other equities analysts have also commented on ALGS. Weiss Ratings lowered Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 28th. Wall Street Zen raised Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a report on Sunday, May 17th. Cantor Fitzgerald restated an “overweight” rating on shares of Aligos Therapeutics in a research report on Friday, May 29th. Finally, Lake Street Capital began coverage on shares of Aligos Therapeutics in a research report on Thursday, May 28th. They issued a “buy” rating and a $45.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $38.50.

Aligos Therapeutics Stock Down 4.8%

ALGS opened at $7.28 on Wednesday. The company’s 50-day moving average price is $5.41 and its 200 day moving average price is $6.40. Aligos Therapeutics has a fifty-two week low of $3.98 and a fifty-two week high of $13.69. The firm has a market cap of $45.06 million, a price-to-earnings ratio of -1.00 and a beta of 2.31.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($1.09) by $0.95. Aligos Therapeutics had a negative net margin of 241.01% and a negative return on equity of 160.72%. The business had revenue of $27.78 million during the quarter, compared to analyst estimates of $24.68 million.

Institutional Investors Weigh In On Aligos Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ALGS. Geode Capital Management LLC lifted its holdings in shares of Aligos Therapeutics by 21.3% during the second quarter. Geode Capital Management LLC now owns 34,048 shares of the company’s stock valued at $246,000 after purchasing an additional 5,978 shares during the last quarter. Rockefeller Capital Management L.P. boosted its position in shares of Aligos Therapeutics by 900.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 10,000 shares of the company’s stock valued at $93,000 after purchasing an additional 9,000 shares during the period. SummitTX Capital L.P. increased its stake in Aligos Therapeutics by 6.7% in the 1st quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock worth $1,106,000 after purchasing an additional 9,375 shares in the last quarter. Susquehanna International Group LLP acquired a new stake in Aligos Therapeutics during the 3rd quarter worth about $99,000. Finally, LPL Financial LLC raised its holdings in Aligos Therapeutics by 19.7% during the 4th quarter. LPL Financial LLC now owns 66,000 shares of the company’s stock worth $615,000 after buying an additional 10,880 shares during the period. Institutional investors and hedge funds own 60.43% of the company’s stock.

Key Headlines Impacting Aligos Therapeutics

Here are the key news stories impacting Aligos Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its EPS forecasts for Aligos’ third and fourth quarters of 2026 to losses of $2.81 and $2.02, respectively, from losses of $3.16 and $2.22. It also improved its FY2026 estimate to a $7.41 loss from a $8.42 loss. Smaller projected losses generally indicate improving financial expectations. HC Wainwright Aligos earnings estimates
• Positive Sentiment: The analyst raised estimates for the third quarter of 2027, fourth quarter of 2027 and fiscal 2030, while retaining a Buy rating. These changes suggest HC Wainwright sees potential for operating improvement over time, even though profitability remains distant. HC Wainwright Aligos forecast revisions
• Neutral Sentiment: Aligos’ shares opened at $7.28, with a market capitalization of approximately $45 million. The stock remains highly volatile, with a beta of 2.31, and is trading above its 50-day moving average but near its 200-day moving average.
• Neutral Sentiment: Reported short interest was zero shares as of August 11, unchanged from July 27, with a zero-day days-to-cover ratio. The figures provide no evidence of meaningful short-selling pressure, although the reported “NaN” percentage change suggests a data-quality issue.
• Negative Sentiment: HC Wainwright lowered its EPS forecasts for the first and second quarters of 2027 and reduced full-year estimates for 2027, 2028 and 2029. The FY2027 forecast fell to a $4.02 loss from $3.56, while FY2028 and FY2029 estimates also worsened, signaling that sustained losses may persist longer than previously expected. HC Wainwright Aligos long-term earnings estimates

About Aligos Therapeutics

Aligos Therapeutics, Inc is a clinical?stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small?molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.